Edition:
India

China NT Pharma Group Co Ltd (1011.HK)

1011.HK on Hong Kong Stock

0.76HKD
22 Feb 2019
Change (% chg)

HK$0.03 (+4.11%)
Prev Close
HK$0.73
Open
HK$0.73
Day's High
HK$0.78
Day's Low
HK$0.73
Volume
1,328,500
Avg. Vol
1,131,687
52-wk High
HK$2.48
52-wk Low
HK$0.68

Latest Key Developments (Source: Significant Developments)

China NT Pharma Group Sees Consol Loss For FY
Wednesday, 30 Jan 2019 

Jan 30 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::GROUP IS EXPECTED TO RECORD CONSOLIDATED LOSS FOR YEAR ENDED 31 DECEMBER 2018.EXPECTED RESULT DUE TO NET LOSS FROM CHANGE IN FAIR VALUE OF FINANCIAL LIABILITIES OF CONVERTIBLE PREFERENCE SHARES IN COMPANY.  Full Article

China NT Pharma Group's Board Approved & Adopted Dividend Policy On Jan 24
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::BOARD APPROVED AND ADOPTED A DIVIDEND POLICY ON JAN 24.  Full Article

China NT Pharma Group Says Unit To Dispose Certain Equity Interests In Suzhou First Pharmaceutical
Tuesday, 8 Jan 2019 

Jan 8 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::UNIT TO DISPOSE CERTAIN EQUITY INTERESTS IN SUZHOU FIRST PHARMACEUTICAL TO BROTHER ENTERPRISES HOLDING.  Full Article

China NT Pharma Group Says Bank Approves Loan Of Up To US$40 Mln To Unit
Wednesday, 3 Oct 2018 

Oct 3 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::SHANGHAI PILOT FREE TRADE ZONE BRANCH OF CHINA MINSHENG BANKING APPROVES 3-YEAR TERM LOAN OF UP TO US$40 MILLION TO UNIT.  Full Article

Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo
Thursday, 19 Apr 2018 

April 18 (Reuters) - China NT Pharma Group Co Ltd <1011.HK>::PFENEX AND NT PHARMA ENTER INTO A DEVELOPMENT AND LICENSE AGREEMENT FOR PFENEX'S PF708 THERAPEUTIC EQUIVALENT CANDIDATE TO FORTEO®.PFENEX INC - PFENEX RECEIVED A PAYMENT OF $2.5 MILLION UPON SIGNING OF AGREEMENT.PFENEX INC - PFENEX MAY BE ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS OF UP TO $22.5 MILLION BASED ON ACHIEVEMENT OF DEVELOPMENT, SALES-RELATED MILESTONES.PFENEX INC - PFENEX MAY ALSO BE ELIGIBLE TO RECEIVE DOUBLE-DIGIT ROYALTIES ON NET PRODUCT SALES.  Full Article

China Nt Pharma Group Co ‍Fy Net Profit Attributable RMB 165.2 Mln VS RMB 116.2 Mln​
Tuesday, 27 Mar 2018 

March 27 (Reuters) - China Nt Pharma Group Co Ltd <1011.HK>::‍FY REVENUE RMB604.8 MILLION VERSUS RMB359.6 MILLION.‍FY NET PROFIT ATTRIBUTABLE RMB165.2 MILLION VERSUS RMB116.2 MILLION​.‍FINAL DIVIDEND OF HK3.5 CENTS PER SHARE​.  Full Article